PlasmarkAD® Pro Max is a breakthrough early detection solution using a simple blood test for Alzheimer’s disease (AD) and related pathology. Utilizing our proprietary machine learning algorithm, the PlasmarkAD® Pro Max test models the presence of brain amyloid-beta pathology with over 96% accuracy based on the levels of 22 AD-associated protein biomarkers (incorporating p-Tau 217, in accordance with the 2024 Revised Diagnosis Criteria from the Alzheimer’s Association). A positive brain amyloid-beta status is consistent with presence of amyloid plaques and Alzheimer’s disease diagnosis. Moreover, it provides a multi-dimensional analysis of various body systems that may be affected by AD, including the immune, metabolic, nervous and vascular systems, enabling personalized analysis and recommendations.